ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
Author:
Open Access
- 16 July 2020
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (7) , 2255
Abstract
The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.Keywords
Funding Information
- National Research Foundation of Korea (2020R1A2C1012484)
This publication has 159 references indexed in Scilit:
- EGFR, FLT1 and Heparanase as Markers Identifying Patients at Risk of Short Survival in CholangiocarcinomaPLOS ONE, 2013
- Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase InhibitorsGastroenterology, 2012
- TargetingPDGFR‐β in CholangiocarcinomaLiver International, 2011
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBritish Journal of Cancer, 2011
- Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomasExperimental and Molecular Pathology, 2010
- Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liverGenes & Development, 2010
- Mucins in cancer: function, prognosis and therapyNature Reviews Cancer, 2009
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinomaBritish Journal of Cancer, 2009
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBritish Journal of Cancer, 2007
- Contact-dependent inhibition of EGFR signaling by Nf2/MerlinJournal of Cell Biology, 2007